Evidence map›Paper›PMID 34382415›Full record

ReviewFuture medicinal chemistry2021

Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets.

Daniel P Flaherty, Mohamed N Seleem, Claudiu T Supuran

Abstract readReview
In one paragraph

Review in Future medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Inhibition of pathogenic bacterial carbonic anhydrases by monothiocarbamates.Journal of enzyme inhibition and medicinal chemistry · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Biological investigation ofJournal of enzyme inhibition and medicinal chemistry · 2022
    Article
  13. The gram-negative bacteriumJournal of enzyme inhibition and medicinal chemistry · 2022
    Article
  14. Activation studies with amino acids and amines of a β-carbonic anhydrase fromJournal of enzyme inhibition and medicinal chemistry · 2022
    Article
  15. Inhibition studies of the protozoan α-carbonic anhydrase fromJournal of enzyme inhibition and medicinal chemistry · 2022
    Article
  16. Molecules (Basel, Switzerland) · 2022
    Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniel P FlahertyDepartment of Medicinal Chemistry & Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.ORCID 0000-0002-8305-0606
Mohamed N SeleemDepartment of Biomedical Sciences & Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute & State University, Blacksburg, VA 24061, USA.ORCID 0000-0003-0939-0458
Claudiu T SupuranDepartment of NEUROFARBA, Section of Pharmaceutical & Nutraceutical Sciences, University of Florence, Polo Scientifico, Firenze, 50122, Italy.ORCID 0000-0003-4262-0323

Funding

Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococciR01AI148523 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Daniel Patrick Flaherty, Mohamed Seleem · 2019 to 2026
$4.2M
NIAID NIH HHS R01 AI148523
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesHumansMicrobial Sensitivity TestsNeisseria gonorrhoeaeAnti-Bacterial AgentsCarbonic Anhydrase InhibitorsCarbonic Anhydrasesantibiotic drug discoverybacterial carbonic anhydrasecarbonic anhydrase inhibitors

Identifiers

PMID34382415
PMCPMC8656345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.